Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

GLOBAL BLOOD THERAPEUTICS, INC.

(GBT)
Delayed Nasdaq  -  04:00 2022-10-04 pm EDT
68.49 USD   +0.01%
10/27Pfizer Completes $5.4 Billion Acquisition Of Sickle Cell Disease Drug Innovator
AQ
10/06BioPharma Credit Receives $175 Million From Global Blood Therapeutics Investment
MT
10/06Global Blood Therapeutics, Inc.(NasdaqGS:GBT) dropped from S&P Global BMI Index
CI
 SummaryQuotesChartsNewsRatingsCalendarCompanyFunds 
Quotes 5-day view   End-of-day quote. End-of-day quote Nasdaq
09/28/2022 09/29/2022 09/30/2022 10/03/2022 10/04/2022 Date
68.11 68.07 68.1 68.48 68.49 Last
2233884 2083094 2683336 3623682 3279961 Volume
-0.10% -0.06% +0.04% +0.56% +0.01% Change
Company
Global Blood Therapeutics, Inc. is a biopharmaceutical company that discovers, develops and delivers treatments. The Company is focused on Oxbryta (voxelotor), which is the Food and Drug Administration (FDA) approved medicine that inhibits sickle hemoglobin (HbS) polymerization, the root cause of red blood cell sickling in sickle cell disease (SCD). It is also advancing its pipeline program in SCD with inclacumab, a... 
More about the company
Ratings of Global Blood Therapeutics, Inc.
Trading Rating : 
Investor Rating :  -
ESG Refinitiv : 
-
More Ratings
All news about GLOBAL BLOOD THERAPEUTICS, INC.
10/27Pfizer Completes $5.4 Billion Acquisition Of Sickle Cell Disease Drug Innovator
AQ
10/06BioPharma Credit Receives $175 Million From Global Blood Therapeutics Investment
MT
10/06Global Blood Therapeutics, Inc.(NasdaqGS:GBT) dropp..
CI
10/06Global Blood Therapeutics, Inc.(NasdaqGS:GBT) dropp..
CI
10/06Global Blood Therapeutics, Inc.(NasdaqGS:GBT) dropp..
CI
10/05Global Blood Therapeutics, Inc. : Entry into a Material Definitive Agreement, Termination ..
AQ
10/05Global Blood Therapeutics, Inc. Announces Cessation of Ted W. Love as Chief Executive O..
CI
10/05Global Blood Therapeutics, Inc. Announces Executive Changes
CI
10/05Global Blood Therapeutics, Inc.(NasdaqGS:GBT) dropp..
CI
10/05Pfizer Inc. (NYSE:PFE) completed the acquisition of Global Blood Thera..
CI
10/04Global Blood Therapeutics, Inc.(NasdaqGS:GBT) dropp..
CI
09/30Global Blood Therapeutics, Inc. : Submission of Matters to a Vote of Security Holders, Oth..
AQ
09/23Global Blood Therapeutics, Inc. : Other Events (form 8-K)
AQ
09/15GBT Supports the Sickle Cell Disease Treatment Centers Act of 2022
AQ
09/08GBT and Sickle Cell Disease Association of America to Host 11th Annual Sickle Cell Dise..
AQ
More news
News in other languages on GLOBAL BLOOD THERAPEUTICS, INC.
10/06BioPharma Credit reçoit 175 millions de dollars de la part de Global Blood Therapeutics..
10/05Global Blood Therapeutics, Inc. annonce la cessation des fonctions de Ted W. Love en ta..
10/05Global Blood Therapeutics, Inc. annonce des changements de direction
10/05Pfizer : finalise l'acquisition de Global Blood Therapeutics
10/05Pfizer Inc. (NYSE:PFE) a finalisé l'acquisition de Global Blood Therap..
More news
Analyst Recommendations on GLOBAL BLOOD THERAPEUTICS, INC.
More recommendations
ETFs positioned on GLOBAL BLOOD THERAPEUTICS, INC.ETFs and Trackers with Trackinsight
ETF WeightVar. 5daysRatingGeography
Virtus LifeSci Biotech Products ETF - USD4.61%7.03%United_States
IQ Merger Arbitrage ETF - USD4.6%-0.25%United_States
AltShares Merger Arbitrage ETF - USD3.16%0.08%-NC
Direxion Fallen Knives ETF - USD2.68%-9.78%-NC
ALPS Medical Breakthroughs ETF - USD1.29%4.65%United_States
More ETFs positioned on GLOBAL BLOOD THERAPEUTICS, INC.
Chart GLOBAL BLOOD THERAPEUTICS, INC.
Duration : Period :
Global Blood Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Managers and Directors
Jeffrey S. Farrow Chief Financial & Accounting Officer
Kim Smith-Whitley Executive VP, Head-Research & Development
Kenneth R. Bridges Medical Director & Vice President-Medical Affairs
Nazila Habibizad Executive Vice President-Operations
Willie Lewis Brown Director-Emeritus
Sector and Competitors
1st jan.Capi. (M$)
GLOBAL BLOOD THERAPEUTICS, INC.133.99%4 621
MODERNA, INC.-28.20%70 055
IQVIA HOLDINGS INC.-22.83%40 441
LONZA GROUP AG-33.82%39 802
ALNYLAM PHARMACEUTICALS, INC.38.22%28 838
SEAGEN INC.-20.82%22 727